Introduction {#Sec1}
============

The intensive multifactorial treatment of hyperglycaemia, hypertension and dyslipidaemia halves the risk of cardiovascular events among patients with long-standing diabetes mellitus and microalbuminuria \[[@CR1], [@CR2]\]. The optimal treatment for individuals identified earlier in the disease trajectory, however, remains unclear \[[@CR3]\]. Intensive multifactorial treatment might be burdensome for patients who are largely asymptomatic. Physicians may be reluctant to introduce intensive treatment (IT) including recommendations to change multiple lifestyle behaviours and the prescription of several medications, which may lead to psychosocial stress and reduced satisfaction with treatment \[[@CR4]\].

Patient-reported outcome measures (PROMs) are a valuable complement to outcomes such as mortality and cardiovascular events when assessing the effectiveness of early treatment. PROMs reflect patients' assessment of their own health and well-being and involve their response to questions on themes such as physical functioning, social functioning and mental well-being. They may include both generic and disease-specific questions.

PROMs are increasingly used as key performance indicators in chronic illness. Their reliability is similar to that of clinical measures such as diastolic BP or blood glucose \[[@CR5]\], and the use of PROMs has been recommended in the evaluation of healthcare services and in regulatory decision-making \[[@CR6]\]. Their routine use provides an opportunity to help drive changes in how healthcare is organised and delivered \[[@CR5]\]. The UK Prospective Diabetes Study (UKPDS) suggested that IT for raised blood glucose levels and BP among British patients newly diagnosed with type 2 diabetes mellitus was not associated with adverse effects on quality of life \[[@CR7]\]. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial of intensive glycaemic control in US patients with long-standing type 2 diabetes mellitus did not lead to an increase in health-related quality of life but was associated with modest improvements in satisfaction with diabetes treatment \[[@CR8]\].

The effects of intensive multifactorial treatment on PROMs among people with type 2 diabetes mellitus detected by screening are not known. The Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care (ADDITION-Europe) was a pragmatic cluster-randomised trial that took place in 343 general practices in Denmark, England and the Netherlands to study the effects of intensive multifactorial treatment compared with routine care (RC) in 3,057 screen-detected patients aged 40--69 years. The prescription of glucose-lowering, antihypertensive and lipid-lowering drugs increased in both groups. After 5 years of follow-up, more patients in the IT group than in the RC group were being prescribed aspirin, ACE inhibitors or angiotensin receptor blockers, glucose-lowering drugs, antihypertensive drugs and lipid-lowering drugs. IT compared with RC was associated with a non-significant 17% relative reduction of cardiovascular mortality and morbidity \[[@CR3]\]. We now report the effects of intensive multifactorial treatment compared with RC on self-reported health status, well-being, diabetes-specific quality of life and treatment satisfaction.

Methods {#Sec2}
=======

Design {#Sec3}
------

The full details of the design and rationale have previously been reported \[[@CR3], [@CR9]--[@CR12]\]. In brief, ADDITION-Europe consisted of two phases: (1) a screening phase, and (2) a pragmatic, cluster-randomised parallel-group trial in four centres (Denmark, Cambridge UK, the Netherlands and Leicester UK). In total, 343 general practices were randomised to screening plus RC of diabetes (the RC group), or to screening followed by intensive multifactorial treatment (the IT group). Randomisation was done in a 1:1 ratio by statisticians in each centre, according to a computer-generated list, independent of measurement teams. Population-based stepwise screening programmes among people aged 40--69 years (50--69 years in the Netherlands) without known diabetes were undertaken between April 2001 and December 2006 \[[@CR13], [@CR14]\]. Individuals were diagnosed with type 2 diabetes mellitus according to the WHO criteria \[[@CR15]\]. Patients were excluded if they had an illness with a life expectancy of less than 12 months, were housebound, pregnant or lactating, or had psychological or psychiatric problems that were likely to invalidate informed consent. In total, 3,057 eligible participants were enrolled (Denmark 1,533, Cambridge UK 867, the Netherlands 498, and Leicester UK 159). The study was approved by local ethics committees in each centre, and the participants provided informed consent.

Intervention {#Sec4}
------------

The interventions to promote the intensified treatment differed slightly in each centre \[[@CR3], [@CR9]--[@CR12]\]. Treatment targets and algorithms were, however, common for the IT group in all centres and included HbA~1c~ \<7.0% (53 mmol/mol), BP ≤135/85 mmHg, cholesterol \<5 mmol/l in the absence of a history of coronary heart disease and \<4.5 mmol/l in patients with a cardiovascular disease, and the prescription of aspirin to those treated with antihypertensive medication. In people with known cardiovascular diseases or a BP above 120/80 mmHg, an ACE inhibitor was recommended. After publication of the Heart Protection Study, the treatment algorithm recommended the prescription of a statin to all patients with a cholesterol concentration of ≥3.5 mmol/l \[[@CR16]\]. Further details are available on the study website ([www.addition.au.dk/](http://www.addition.au.dk/), accessed 10 July 2013). In the RC group, patients with screen-detected diabetes received the standard pattern of diabetes care with less strict targets according to the national guidelines in their respective countries \[[@CR17]--[@CR19]\].

Measurements and outcomes {#Sec5}
-------------------------

### Anthropometric and biochemical measurements {#d30e542}

All measures were undertaken following standard operating procedures by centrally trained staff unaware of the study group allocation. Biochemical measures were analysed in five regional laboratories, without any systematic differences in the HbA~1c~ measures \[[@CR13]\]. Participants were followed for a mean of 5.7 years.

### Questionnaires {#d30e553}

At baseline, standardised self-report questionnaires were used to collect information on education, employment, ethnicity, lifestyle habits (smoking status and alcohol consumption), prescribed medication and health status (Euroqol 5 Dimensions \[EQ-5D\]). As the participants were screen-detected, no diabetes-specific measures were obtained at baseline. At follow-up, the following questionnaires were used to cover both generic and diabetes-specific measures. Questionnaires were completed at the same health assessment visit as the anthropometric and biochemical measurements.

Health status was assessed using the 36-item Short Form Health Survey (SF-36), which generates a profile of scores on eight dimensions of health: (1) physical functioning; (2) role limitations caused by physical problems; (3) social functioning; (4) bodily pain; (5) general mental health; (6) role limitations due to emotional problems; (7) vitality; and (8) general health perceptions. Two summary scales can be calculated: the physical component score and the mental component score. For all dimensions, an average score can be calculated, with a range from 0 (least favourable health state) to 100 (most favourable health state) \[[@CR20]\].

The EQ-5D is a generic questionnaire consisting of a classification system (EQ-5D Profile) and a Visual Analogue Scale (EQ-VAS). The EQ-5D Profile was completed by participants at baseline and follow-up; the EQ-VAS was completed only at follow-up. The EQ-5D Profile covers five domains of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each with three levels of functioning: level 1, no problems; level 2, some problems; and level 3, severe problems. This results in 243 health states, with a score ranging from −0.594 to +1.00 (full health). A value of zero represents death; negative values imply a health state worse than death. An interaction term adjusts for an extra decrease when one of the dimensions is at the most severe level \[[@CR21]\]. The EQ-VAS is a graded, vertical line anchored at 0 (worst imaginable health state) and 100 (best imaginable health state). The patient was asked to mark a point on the EQ-VAS that best reflected his or her actual health state \[[@CR22]\].

General well-being was assessed with the 12-item short form of the Well-Being Questionnaire (W-BQ12), which measures different aspects of well-being of study participants, including patients with diabetes \[[@CR23]\]. It can be scored on three subscales, each containing four items and with a score range of 0--12: negative well-being (a higher score meaning more negative well-being), energy (a higher score meaning more energy) and positive well-being (a higher score representing more positive well-being). Furthermore, a score for general well-being can be calculated \[[@CR24]\], with a score range of 0--36 and a higher score indicating better well-being.

The Audit of Diabetes-Dependent Quality of Life (ADDQoL) is a measure of how patients perceive the impact and importance of diabetes and its treatment on quality of life \[[@CR25]\]. We used the ADDQoL 19, which consists of 19 diabetes-specific items. For each item, the patient is asked how things would be without diabetes, with a score ranging from −3 (a great deal better) to 1 (worse), and then asked to rate the importance of this item, scores ranging from 3 (very important) to 0 (not at all important). A weighted rating per item can be calculated by multiplying the unweighted rating by the importance rating. The total ADDQoL score is the mean of all the weighted ratings of the applicable domains, and ranges from −9 (the maximum negative impact of diabetes) to 3 (the maximum positive impact of diabetes).

The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is recommended for measuring patients' satisfaction with their diabetes treatment \[[@CR26]\]. It consists of a six-item scale assessing treatment satisfaction and two items assessing the perceived frequency of hyperglycaemia and hypoglycaemia. The treatment satisfaction score can range from 0 (very dissatisfied) to 36 (very satisfied).

Statistical analyses {#Sec6}
--------------------

The analysis plan was finalised prior to preparation of the endpoint dataset (<http://www.addition.au.dk/>, accessed 10 July 2013). We compared the baseline characteristics of surviving participants who did and who did not complete both the baseline and 5-year questionnaires. For normally distributed continuous variables, we calculated means and SDs, and for non-normal variables we presented medians and 25th and 75th percentiles. For categorical variables, we calculated the number and percentage of individuals within each category. We presented the mean scores and SDs of all PROMs at follow-up by centre and by randomised group. We used linear mixed effects regression models to estimate the difference in each PROM at follow-up, and 95% CIs, comparing the IT group with the RC group. A random effect per general practice was included in order to account for intra-cluster correlation. All PROMs were left-skewed. As an alternative to transformation, we wished to control for the baseline level of the PROMs. These were not available for all measures so we included baseline EQ-5D as a proxy for baseline quality of life; correction for baseline EQ-5D greatly improved the normality of the residuals.

The estimated differences in means from the four centres were then pooled using random effects meta-analysis, and a forest plot was used to display the estimated mean differences and CIs for each centre and overall. We calculated the *I*^*2*^ statistic to represent the proportion of variability between centres owing to heterogeneity.

Individuals who were lost to follow-up or did not complete both the baseline and follow-up questionnaires were excluded. Patients with missing data might have been those who were experiencing more serious illness and greater disability. These missing data are therefore unlikely to be 'missing completely at random' but rather 'missing at random', so simply excluding these patients may lead to selection bias. Therefore, we used multiple imputation \[[@CR27]\], imputing five datasets using patient characteristics at baseline and at the 5-year follow-up and including all patients who were alive at follow-up, to perform a sensitivity analysis.

Analyses were undertaken using SAS v9.2 (SAS Institute, Cary, NC, USA) and Review Manager v5.1 (Cochrane Collaboration, <http://ims.cochrane.org/revman>).

Results {#Sec7}
=======

Of the 343 randomised general practices, 318 (157 RC and 161 IT) completed screening and included eligible patients. At baseline, the participating practices had a prevalence of diabetes of 3.5% and nationally representative mean patient list sizes \[[@CR3]\]. Baseline demographic, clinical, biochemical and treatment characteristics of the 3,057 participants in the RC and IT groups were well matched overall. Their mean age at baseline was 60.3 years, 58% were male, 94% were white and 41% were employed \[[@CR3]\].

The participant and practice flows are shown in Fig. [1](#Fig1){ref-type="fig"}. Data from the 2,861 patients included in the multiple imputation analyses are shown in Table [1](#Tab1){ref-type="table"}. Patients who completed the questionnaires at both baseline and follow-up (*n* = 2,217) were more likely to be male (59.5% vs 50.8%), of white ethnicity (95.2% vs 89.9%) and employed (44.8% vs 32.7%) than those who did not (*n* = 644). The former group were also less likely to be current smokers (24.3% vs 34.0%), have higher levels of alcohol consumption (median 5 units/week vs 3 units/week) and have higher EQ-5D scores at baseline (median 0.85 vs 0.81). They also had lower systolic BP (148.5 mmHg vs 151.4 mmHg). Other variables were comparable between the two groups (data not shown).Fig. 1Practice and participant flows in the ADDITION-Europe trialTable 1Baseline characteristics of ADDITION-Europe participants who were included in the multiple imputation analysisRCIT(*n* = 1,287)*n* available(*n* = 1,574)*n* availableDemographic variables Male sex731 (56.8%)1,287916 (58.2%)1,574 Mean (SD) age at diagnosis (years)60.0 (6.9)1,28760.1 (6.9)1,574 White ethnicity1,157 (92.8%)1,2471,440 (95.1%)1,514 Employed403 (43.1%)935465 (41.7%)1,116Clinical variables History of myocardial infarction67 (5.6%)1,19999 (6.6%)1,498 History of stroke20 (1.7%)1,18339 (2.7%)1,465 Current smoker337 (26.8%)1,257405 (26.1%)1,549 Median (IQR) units of alcohol /week5 (1,12)1,1054 (1, 12)1,399 Mean (SD) BMI (kg/m^2^)31.6 (5.5)1,25231.6 (5.5)1,517 Mean (SD) weight (kg)90.3 (17.3)1,25491.0 (17.6)1,518 Median (IQR) HbA~1c~ (mmol/mol)49 (43, 56)1,21148 (43, 56)1,492 Median (IQR) HbA~1c~ (%)6.6 (6.1, 7.3)1,2116.5 (6.1, 7.3)1,492 Mean (SD) systolic BP (mmHg)149.9 (21.1)1,257148.4 (22.0)1,518 Mean (SD) diastolic BP (mmHg)86.8 (11.2)1,25786.1 (11.1)1,519 Mean (SD) total cholesterol (mmol/l)5.6 (1.2)1,2135.5 (1.1)1,498 Median (IQR) HDL cholesterol (mmol/l)1.2 (1.0, 1.5)1,2021.2 (1.0, 1.5)1,476 Median (IQR) triacylglycerol (mmol/l)1.7 (1.2, 2.4)1,2081.6 (1.2, 2.3)1,487Self-reported medication use Any antihypertensive drugs545 (43.5%)1,254699 (46.3%)1,510 Any cholesterol-lowering drugs188 (15.0%)1,254258 (17.1%)1,510 Aspirin152 (12.1%)1,254230 (15.2%)1,510Self-reported health status Median (IQR) EQ-5D score0.85 (0.73, 1.00)1,2040.85 (0.73, 1.00)1,491 Included in complete case analysis967 (75.1%)1,2871,250 (79.4%)1,574Data are *n* (%) unless otherwise specifiedIQR, interquartile range

EQ-5D values did not change between diagnosis and follow-up, with a median (interquartile range) of 0.85 (0.73--1.00) at baseline and 0.85 (0.73--1.00) at 5-year follow-up. Table [2](#Tab2){ref-type="table"} shows the PROM scores at follow-up separately for each centre and by randomised group.Table 2PROMs at follow-up, by centre and by randomised group, in the ADDITION-Europe trialPROMDenmarkCambridgeLeicesterThe NetherlandsITRCITRCITRCITRC*n*Value*n*Value*n*Value*n*Value*n*Value*n*Value*n*Value*n*ValueSF-36 Physical component score66546.7 (10.0)42846.7 (9.6)35043.9 (11.6)31044.6 (11.3)5944.3 (11.4)8443.4 (10.5)17746.8 (10.4)14447.0 (10.5) Mental component score66555.3 (9,1)42854.9 (8.5)35053.4 (9.0)31054.6 (8.4)5950.9 (10.1)8452.2 (9.8)17754.3 (8.2)14453.7 (7.4)Euroqol EQ-5D6950.85 (0.21)4630.84 (0.22)3510.81 (0.23)3120.83 (0.22)600.75 (0.31)850.79 (0.23)1760.86 (0.18)1440.82 (0.26) EQ-VAS69176.9 (16.9)46276.4 (18.5)35576.1 (18.0)31678.4 (16.4)6078.3 (16.3)8874.8 (18.4)17576.5 (13.7)14475.3 (15.6)W-BQ12 General68028.5 (5.9)44728.1 (6.3)34625.5 (6.5)31026.4 (5.9)5825.3 (6.7)7825.0 (6.3)17127.6 (6.3)14127.4 (5.7) Negative6891.1 (2.0)4581.1 (1.8)3511.7 (2.4)3141.4 (2.1)591.9 (2.5)862.1 (2.5)1751.1 (1.9)1431.1 (1.8) Energy6918.1 (2.7)4538.0 (2.8)3527.0 (2.7)3157.3 (2.6)587.1 (2.7)827.1 (2.3)1748.5 (2.6)1428.5 (2.3) Positive6929.4 (2.5)4569.2 (2.8)3528.2 (2.8)3158.4 (2.7)598.2 (2.6)858.0 (2.9)1778.0 (3.1)1448.1 (2.6)ADDQoL552−0.73 (1.15)348−0.69 (1.07)315−0.84 (1.29)271−0.87 (1.30)50−1.20 (1.78)76−2.39 (2.52)169−0.55 (0.86)135−0.55 (0.92)DTSQ64830.9 (6.2)40530.1 (6.7)34431.5 (4.9)30531.2 (5.4)6033.0 (3.8)8529.1 (7.3)17431.2 (5.6)14031.0 (5.6)Data are expressed as mean (SD)

The mean differences in the PROMs comparing the IT group with the RC group are shown in Figs [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"} and electronic supplementary material (ESM) Fig. [1](#MOESM1){ref-type="media"}. There were no statistically significant differences in health status (Fig. [2](#Fig2){ref-type="fig"}; for SF-36, the summary scales are presented in Fig. [2](#Fig2){ref-type="fig"} and the eight subscales are presented in ESM Fig. [1](#MOESM1){ref-type="media"}), well-being (Fig. [3](#Fig3){ref-type="fig"}), diabetes-specific quality of life (Fig. [4](#Fig4){ref-type="fig"}) and satisfaction with diabetes treatment (Fig. [5](#Fig5){ref-type="fig"}) between the IT and RC groups. There was some heterogeneity between centres, with *I*^*2*^ varying between 13% (SF-36 physical functioning) and 73% (EQ-VAS).Fig. 2Mean difference in health status between the IT and RC groups after 5 years of follow-up by centre (boxes) and pooled estimates (diamonds) calculated by random effects meta-analysis. The widths of the horizontal bars and diamonds denote the 95% CI, and the box sizes indicate the relative weight in the analysis. MCS, mental component scale; PCS, physical component scaleFig. 3Mean difference in scores from the W-BQ12 between the IT and RC groups after 5 years of follow-up by centre (boxes) and pooled estimates (diamonds) calculated by random effects meta-analysis. The widths of the horizontal bars and diamonds denote the 95% CI, and the box sizes indicate the relative weight in the analysisFig. 4Mean difference in scores from the ADDQoL questionnaire between the IT and RC groups after 5 years of follow-up by centre (boxes) and pooled estimates (diamonds) calculated by random effects meta-analysis. The widths of the horizontal bars and diamonds denote the 95% CI, and the box sizes indicate the relative weight in the analysisFig. 5Mean difference in scores from the DTSQ between the IT and RC groups after 5 years of follow-up by centre (boxes) and pooled estimates (diamonds) calculated by random effects meta-analysis. The widths of the horizontal bars and diamonds denote the 95% CI, and the box sizes indicate the relative weight in the analysis

Multiple imputation analyses resulted in slightly different point estimates, but the overall patterns were unchanged, with no statistically significant differences in any of the PROMs (results not shown).

Discussion {#Sec8}
==========

An intervention to promote the multifactorial target-driven, intensive management of patients with screen-detected type 2 diabetes mellitus was not associated with differences in health status, well-being, quality of life and treatment satisfaction compared with routine diabetes care after a mean follow-up of 5.7 years. Health status (as measured by the EQ-5D) did not change between diagnosis and follow-up.

The trial was undertaken during a period in which targets for BP and cholesterol levels became stricter for diabetes patients, which resulted in smaller than expected differences between the RC and IT groups, in terms of cardiovascular risk factors, prescribed medication and cardiovascular disease outcomes \[[@CR3]\]. The differences were larger in the first years of the trial, and 1 year differences in intermediate outcomes between the RC and IT groups were not maintained at 5 years \[[@CR10], [@CR28]\]. As a result, the difference in PROMs between the two study groups may have been reduced. However, we also found that there were no differences in SF-36 and EQ5D scores between the treatment groups at 1 and 3 years in the Dutch arm of the trial \[[@CR10], [@CR29]\]. Although pooled analyses from the four centres showed no differences overall between the IT and RC groups, for some PROMs (the SF-36 physical component scale, EQ-VAS, ADDQoL and DTSQ), the results from Leicester clearly favoured the IT group. This may be due to the multiethnic population in Leicester and the nature of the intervention, which was delivered by an intermediate care team comprising a specialist doctor, diabetes nurse educator and dietitian who were based at a community-based diabetes specialist care facility. Patients received structured education via the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) programme \[[@CR30]\], weight management advice and a glucometer at diagnosis. This is in contrast to other ADDITION centres, which relied more heavily upon the incumbent primary care team to achieve the targets set out in the IT protocols \[[@CR28]\]. The different responses to intensive multifactorial treatment for type 2 diabetes mellitus immediately after screening across different populations and healthcare settings require further research.

Our study had several strengths. The sample size and follow-up of the study population were robust, and the response rate (73%) was high. We used both generic and diabetes-specific measures: disease-specific tools are better than generic tools at quantifying temporal changes in quality of life \[[@CR31]\]. This analysis clearly demonstrated differential effects of the intervention on PROMs across the different populations.

Our study also had some limitations. The patients who completed all the questionnaires differed from those who did not. These differences were, however small, not in one direction and similar for the IT and RC groups, so they are likely to have had only a small effect on the outcomes. The sensitivity analysis using multiple imputation confirmed the results of the main analysis, which strengthens our belief that a selective dropout of patients did not introduce significant bias. Most PROMs were not measured at baseline, which meant we were unable to investigate changes in PROMs over time. For diabetes-specific outcomes, such as the DTSQ and ADDQoL, this would not have been possible. We measured a wide range of possible confounding variables and these were similar between the groups at baseline. We would have preferred to correct each outcome for its corresponding baseline measurement, but for most PROMs no baseline measurement was available. As a proxy for baseline health status, we adjusted all models for the baseline EQ-5D level.

In contrast to other diabetes studies, the participants in ADDITION-Europe were screen-detected and hence the majority were asymptomatic. Their baseline health-related quality of life was high (median EQ-5D 0.85 on a scale with a maximum of 1.0) and remained stable over the first years of the disease, although the participants aged 5 years over the course of the study. This is an important result, particularly given the increased treatment burden over this time. In a Dutch study of 1,136 people with type 2 diabetes mellitus (mean age 64.9 years, 50% women), the average EQ-5D score was 0.74 (SD 0.27). Women, older patients and patients with a longer duration of diabetes reported lower health-related quality of life \[[@CR31]\].

In a cluster-randomised trial in 55 Dutch primary care practices, changes in diabetes-related health status did not differ between the standard and intensive groups after 1 year of intensified multifactorial therapy, although some detrimental effects on social functioning (SF-36 social functioning showing a mean intention-to-treat difference in change between groups of −1.03) could not be ruled out \[[@CR32]\]. The participants were 4 years older than the ADDITION-Europe participants, were largely white and had a mean duration of diabetes of 6 years. Their baseline EQ-5D values were 0.82 (intervention group) and 0.84 (control group).

The UKPDS reported that intensified treatment of blood glucose and BP in patients newly diagnosed with diabetes mellitus did not adversely affect their health status \[[@CR7]\]. In the ACCORD sub-study, participants were about 2 years older than the ADDITION-Europe patients, had a different ethnic background and had had clinically diagnosed type 2 diabetes mellitus for 9--10 years; in addition, 35% were on insulin treatment. The change over 4 years in the SF-36 physical component score and the DTSQ scale differed significantly between the standard and intensive glucose-lowering treatment groups. However, the absolute net difference in the physical component score was only 0.5 units, far below a general threshold of three to five points for a minimally important difference of these measures \[[@CR8]\]. Other results are largely in line with ADDITION-Europe findings, which means that there were no clinically significant differences in PROMs between treatment groups.

We have found that, following detection by screening, intensive multifactorial treatment over 5 years was not associated with differences in health status, well-being, quality of life or treatment satisfaction compared with RC. While it remains uncertain whether early IT is associated with a reduction in cardiovascular endpoints, we find no evidence that such treatment adversely affects patient-reported outcomes early in the course of the disease.
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